Seattle genetics announces initiation of phase 3 clinical trial of tucatinib in combination with ado-trastuzumab emtansine (t-dm1, kadcyla®) for patients with advanced or metastatic her2-positive breast cancer

Seattle genetics, inc. announced dosing of the first patient in her2climb-02, a randomized phase 3 clinical trial evaluating investigational agent tucatinib versus placebo, in combination with standard-of-care ado-trastuzumab emtansine (t-dm1, kadcyla), for patients with locally advanced or metastatic her2-positive (her2+) breast cancer. this trial is intended to support registration in the u.s. tucatinib is an oral, small molecule tyrosine kinase inhibitor that is highly selective for her2. her2climb-02 is a multi-center, randomized, double-blind, placebo-controlled phase 3 trial designed to evaluate tucatinib versus placebo, in combination with t-dm1, in patients with unresectable locally-advanced or metastatic her2+ breast cancer, including those with brain metastases, who have had prior treatment with a taxane and trastuzumab in any setting.
SGEN Ratings Summary
SGEN Quant Ranking